Page 1 | Search Results | Blood | American Society of Hematology

1-9 of 9

Sort by

Sort Order Select

Journal Articles

Ricolinostat (ACY-1215), the First Selective HDAC6 Inhibitor, Combines Safely with Pomalidomide and Dexamethasone and Shows Promosing Early Results in Relapsed-and-Refractory Myeloma (ACE-MM-102 Study)

Noopur S. Raje, MD, William Bensinger, MD, Craig E. Cole, MD, Sagar Lonial, MD, Sundar Jagannath, MD, Carlos E. Arce-Lara, MD, Jason Valent, MD, Ashley E Rosko, MD, Wael A. Harb, MD, Irwindeep Sandhu, MD, Nizar J Bahlis, MD, Donna Reece, Evangelos Terpos, MD, Jeffrey Supko, PhD, David Tamang, PhD, Simon S Jones, PhD, Catherine Wheeler, MD, Robert J Markelewicz, Jr., MD, Paul G. Richardson

Blood (2015) 126 (23): 4228.

https://doi.org/10.1182/blood.V126.23.4228.4228

Published: 2015

Journal Articles

A Multicenter Phase II Study Using a Dose Intensified Pegylated-Asparaginase Pediatric Regimen in Adults with Untreated Acute Lymphoblastic Leukemia: A DFCI ALL Consortium Trial

Daniel J. DeAngelo, MD PhD, Kristen Stevenson, MS, Donna S Neuberg, ScD, Lewis B. Silverman, MD, Karen K. Ballen, MD, Julie D. Asch, MD, Yasser Abou Mourad, MD, Kristjan Paulson, MD FRCPC, Matthew D. Seftel, MBChB, FRCP(C), MRCP, David Avigan, MD, Julie Bergeron, MD, Stephen Couban, MD, William Blum, MD, John Storring, MD, Martha Wadleigh, MD, David P. Steensma, MD, Jeffrey Supko, PhD, Stephen E. Sallan, MD, Richard M. Stone, MD

Blood (2015) 126 (23): 80.

https://doi.org/10.1182/blood.V126.23.80.80

Published: 2015

Journal Articles

Ricolinostat (ACY-1215), the First Selective HDAC6 Inhibitor, in Combonation with Lenalidomide and Dexamethasone in Patients with Relapsed and Relapsed-and-Refractory Multiple Myeloma: Phase 1b Results (ACE-MM-101 Study)

Andrew J. Yee, MD, William Bensinger, MD, Peter M. Voorhees, MD, Jesus G. Berdeja, MD, Paul G. Richardson, MD, Jeffrey Supko, PhD, David Tamang, PhD, Simon S Jones, PhD, Catherine Wheeler, MD, Robert J Markelewicz, Jr., MD, Noopur S. Raje, MD

Blood (2015) 126 (23): 3055.

https://doi.org/10.1182/blood.V126.23.3055.3055

Published: 2015

Journal Articles

Ricolinostat (ACY-1215), the First Selective HDAC6 Inhibitor, in Combination with Bortezomib and Dexamethasone in Patients with Relapsed or Relapsed-and-Refractory Multiple Myeloma: Phase 1b Results (ACY-100 Study)

Dan T. Vogl, MD, Noopur S. Raje, MD, Sundar Jagannath, MD, Paul G. Richardson, MD, Parameswaran Hari, MD MRCP, MS, Robert Z. Orlowski, PhD, MD, Jeffrey Supko, PhD, David Tamang, PhD, Simon S Jones, PhD, Catherine Wheeler, MD, Robert J Markelewicz, Jr., MD, Sagar Lonial, MD

Blood (2015) 126 (23): 1827.

https://doi.org/10.1182/blood.V126.23.1827.1827

Published: 2015

Journal Articles

Administration of Erwinia Asparaginase (Erwinase®) Following Allergy to PEG-Asparaginase In Children and Young Adults with Acute Lymphoblastic Leukemia Treated on AALL07P2 Achieves Therapeutic Nadir Serum Asparaginase Activity: A Report From the Children's Oncology Group (COG)

Wanda Salzer, MD, Barbara Asselin, MD, Jeffrey Supko, PhD, Meenakshi Devidas, PhD, Nicole Kaiser, RPh, Paul V. Plourde, MD, Naomi Winick, MD, Gregory Reaman, MD, Elizabeth Raetz, MD, William L. Carroll, MD, Stephen Hunger, MD

Blood (2010) 116 (21): 2134.

https://doi.org/10.1182/blood.V116.21.2134.2134

Published: 2010

Journal Articles

Phase I Trial of Vorinostat (SAHA) in Combination with Alvocidib (Flavopiridol) in Patients with Relapsed, Refractory or (Selected) Poor Prognosis Acute Leukemia or Refractory Anemia with Excess Blasts-2 (RAEB-2)

Steven Grant, MD, Sarah Kolla, Leonardo Andres Sirulnik, MD, PhD, Geoffrey Shapiro, Jeffrey Supko, Brenda Cooper, Edward Perkins, Viswanathan Ramakrishnan, Igor Espinoza-Delgado, MD, M B Tombes, John D Roberts

Blood (2008) 112 (11): 2986.

https://doi.org/10.1182/blood.V112.11.2986.2986

Published: 2008

Journal Articles

A Multicenter Phase II Study Using a Dose Intensified Pediatric Regimen in Adults with Untreated Acute Lymphoblastic Leukemia.

Daniel J. DeAngelo, MD, PhD, Suzanne Dahlberg, PhD, Lewis B. Silverman, MD, Stephen Couban, MD, Philip C. Amrein, MD, Matthew D. Seftel, MD, A. Robert Turner, MD, Brian Leber, MD, Kang Howsan-Jan, MD, Martha Wadleigh, MD, L. Andres Sirulnik, MD, Jeffrey Supko, PhD, Ilene Galinsky, Stephen E. Sallan, MD, Richard M. Stone, MD

Blood (2007) 110 (11): 587.

https://doi.org/10.1182/blood.V110.11.587.587

Published: 2007

Journal Articles

Intravenous PEG Asparaginase during Remission Induction for Childhood ALL.

Lewis B. Silverman, Kristen Stevenson, Donna Neuberg, Jane O’Brien, Jeffrey Supko, Stephen E. Sallan

Blood (2006) 108 (11): 1854.

https://doi.org/10.1182/blood.V108.11.1854.1854

Published: 2006

Journal Articles

Pharmacodynamics and Tolerability of Twice-Weekly Erwinia Asparaginase after E. coli Asparaginase Allergy in Children with ALL.

Lewis B. Silverman, Donna Neuberg, Jeffrey Supko, Mary Relling, Christina Woodward, Stephen E. Sallan

Blood (2006) 108 (11): 1857.

https://doi.org/10.1182/blood.V108.11.1857.1857

Published: 2006

NARROW

Ricolinostat (ACY-1215), the First Selective HDAC6 Inhibitor, Combines Safely with Pomalidomide and Dexamethasone and Shows Promosing Early Results in Relapsed-and-Refractory Myeloma (ACE-MM-102 Study)

A Multicenter Phase II Study Using a Dose Intensified Pegylated-Asparaginase Pediatric Regimen in Adults with Untreated Acute Lymphoblastic Leukemia: A DFCI ALL Consortium Trial

Ricolinostat (ACY-1215), the First Selective HDAC6 Inhibitor, in Combonation with Lenalidomide and Dexamethasone in Patients with Relapsed and Relapsed-and-Refractory Multiple Myeloma: Phase 1b Results (ACE-MM-101 Study)

Ricolinostat (ACY-1215), the First Selective HDAC6 Inhibitor, in Combination with Bortezomib and Dexamethasone in Patients with Relapsed or Relapsed-and-Refractory Multiple Myeloma: Phase 1b Results (ACY-100 Study)

Administration of Erwinia Asparaginase (Erwinase®) Following Allergy to PEG-Asparaginase In Children and Young Adults with Acute Lymphoblastic Leukemia Treated on AALL07P2 Achieves Therapeutic Nadir Serum Asparaginase Activity: A Report From the Children's Oncology Group (COG)

Phase I Trial of Vorinostat (SAHA) in Combination with Alvocidib (Flavopiridol) in Patients with Relapsed, Refractory or (Selected) Poor Prognosis Acute Leukemia or Refractory Anemia with Excess Blasts-2 (RAEB-2)

A Multicenter Phase II Study Using a Dose Intensified Pediatric Regimen in Adults with Untreated Acute Lymphoblastic Leukemia.

Intravenous PEG Asparaginase during Remission Induction for Childhood ALL.

Pharmacodynamics and Tolerability of Twice-Weekly Erwinia Asparaginase after E. coli Asparaginase Allergy in Children with ALL.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only